As a mage, I just want to pursue the truth

Chapter 26
During the epidemic, endorphin has excellent analgesic effect in critically ill patients, and α-endorphin not only has excellent analgesic effect, but also can make patients feel relaxed and happy.

The large donation of Kechuang Biotech during the epidemic and the excellent performance of Endorphin in Jiangcheng have allowed Endorphin to develop rapidly in the domestic market.

It is precisely because of the good performance of the epidemic that when the epidemic in American soared, the FDA accelerated the approval of endorphin, and after the approval of endorphin, it was launched in American.

"It's not that I don't supply, it's that our production capacity is really limited. Our annual production capacity is only 8000L. The domestic supply needs to be stable, and American must also supply. We don't have any spare goods to supply to Lion City." Cheng Gang explained road.

"Representatives from Europa's representative office in Shenhai came to Kechuang Biotech two days ago. They hoped that we could provide Europa with a batch of drugs, saying that they could buy them at twice the price."

"We still refused. Insufficient production capacity is the biggest limitation for our current development."

Since the number of confirmed cases in the Lion City exceeded 2 at the end of February, it is now May, and the daily number of confirmed cases in the Lion City is above double digits.

The epidemic may break through the medical defense line of the Lion City at any time. For endorphins, which performed well during the epidemic, the Lion City would like to buy a batch of drugs.

Endorphins are now equivalent to monopoly properties, and only Kechuang Bio can provide them.

However, since the analgesic market is not a monopoly, and there are a series of drugs such as morphine and fentanyl competing with it, it is impossible to sue Kechuang Bio in the name of monopoly.

Ho Ching, head of Temasek's science and technology innovation project, said:
"As a shareholder of Kechuang Biology, it is normal for us to get some production capacity? And if the production capacity is insufficient, we will expand production. Now that the global epidemic is developing rapidly, the market for endorphins is very broad."

"Our valuation at the time was based on the fact that endorphin could account for 40.00% of the global analgesic market share, and now it is entirely possible to account for 60.00% to [-]% of the market share."

"Now that the market is so promising, we should go and capture the market."

"Don't say so much, at least guarantee to give me 5.00% of the production capacity, my shares account for 5.00%, and give me 5.00% of the production capacity."

Temasek is the sovereign fund of Lion City, which to a certain extent represents the will of the country. At the time when the epidemic broke out globally, medicines were more precious than gold.

"We in the Lion City are willing to buy endorphins at three times the price."

In the black market, endorphin is a hard currency with a price but no market. Compared with the ex-factory price of Kechuang Bio, the black market price has at least tripled.

Because this thing belongs to the late stage of the new crown, a dose can have a cardiotonic effect, and it is possible to survive after a shot of endorphins.

Cheng Gang: "I also want to expand production capacity. The problem is that it takes time to expand production capacity. The industrial production of endorphin has high requirements for operators. Our current operators have been trained for half a year before starting to work."

"The good product rate after they took up the job was less than 80.00% in the early stage, and it is only slowly increasing now."

"The fully automated production line of endorphin is still in the bidding stage, and it has not yet been determined which manufacturer will do it."

"There is still $50 billion in cash lying on the books of Kechuang Biology. We are not short of money now. Expansion of production capacity is not just a matter of money. We need to respect the objective laws of the development of things."

"Because of the epidemic, in order to expand our production capacity, we have recently recruited masters and even doctors who have started to go to the front line of production."

"As for the 5.00% share to the Lion City, Kechuang Bio's production capacity for the next eight months has been locked in advance by companies from American and Huaguo. We have already signed a contract, and there is no room for production to be given to the Lion City."

"Let's not talk about you today, even if Chairman Zheng asks me, I can't provide production to Lion City."

He Jing asked: "Can Kechuang Biotech authorize the biomedical companies in Lion City to produce endorphins?"

Cheng Gang: "Authorization is possible, but there are a few questions. How to charge the authorization fee?"

"If you authorize biomedical companies in the Lion City, do you also have to authorize other international pharmaceutical companies?"

"In addition, it will take at least half a year from authorization to your start of production. What is the development of the epidemic in half a year?"

"Without the support of Kechuang Bio's technical staff, your official production time will be more than half a year, but we can't find any manpower to help you build the factory now, and it is too late for us to expand our production capacity."

"And whether to authorize the synthesis pathway of endorphin to other pharmaceutical companies, this matter needs to be decided by Chairman Zheng. I haven't seen Chairman Zheng for at least three months."

"Only Mr. Li of Kechuang Biology can see Zheng Dong once a month to report on his work. The next time she sees Zheng Zheng is three days later. I can ask her to ask Zheng Zheng's opinion."

"I can't presume to make decisions on this critical issue right now."

"There are many biopharmaceutical companies in Lion City, and they can first make a batch of endorphins through laboratory methods for backup."

"Or you can discuss with McKesson and ask them to spare some production capacity for you."

McKesson is an American pharmaceutical sales company that locked part of endorphin production capacity in advance.

He Jing knew that her pressure had failed: "I hope to get an answer from Director Zheng as soon as possible. Also, please ask Mr. Zheng if he can optimize the industrial production process."

"Expand production capacity ahead of schedule."

The status quo of Kechuang Biology is that it is not short of money. There is money lying on the books that cannot be spent, and the supply of products is still in short supply.

There have been voices in the domestic securities market, which mean that Kechuang Bio should be listed on the Science and Technology Innovation Board, and Kechuang Bio's listing on the Science and Technology Innovation Board must be the leader of the Science and Technology Innovation Board.

Shareholders even joked that the name of Kechuangbio was born for the Science and Technology Innovation Board. The reason why the Science and Technology Innovation Board has not improved since its establishment is because Kechuangbio has not been listed on the Science and Technology Innovation Board.

So much so that when the leaders of the China Securities Regulatory Bureau came to Suzhou, they investigated Kechuangbio, and asked when Kechuangbio planned to go public and whether it would consider listing on the Science and Technology Innovation Board.

Domestic Internet companies generally go to NASDAQ or Hong Kong stock market for listing, and domestic pharmaceutical companies generally choose domestic or Hong Kong stock market for listing.

Because American has no shortage of excellent pharmaceutical companies, domestic pharmaceutical companies cannot get a good valuation when they go public on American.

Now that the market is in a bad situation, the outside world is looking forward to when Kechuang Bio will go public. Kechuang Bio itself is not in a hurry, and they are not short of money at all.

Generally, companies go public because they need to raise funds to enable the company to develop better, which is a stage that is needed during development.

Even Bank of Communications International is not in a hurry to list Kechuang Biotech, let alone several other investment institutions.

They hope that Kechuang Bio will develop for a period of time and have a better valuation before going public.

It is best to go public in 2021, because affected by the epidemic in 2020, Kechuang Bio's financial report in 2020 will definitely be particularly good.

(End of this chapter)